Can-Fite BioPharma Ltd. (IL:CANF)
TASE:CANF
CANF Stock Chart & Stats
732.30
>-0.01(-4.76%)
At close: 4:00 PM EST
732.30
>-0.01(-4.76%)
Day’s Range― - ―
52-Week Range500.00 - 6,000.00
Previous CloseN/A
Volume13.23M
Average Volume (3M)1.04M
Market Cap
₪22.42M
Enterprise Value8.53B
Total Cash (Recent Filing)₪6.46M
Total Debt (Recent Filing)₪90.00K
Price to Earnings (P/E)―
Beta-0.46
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-25.73
Shares Outstanding4,285,093
10 Day Avg. Volume130,742
30 Day Avg. Volume1,039,800
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.77
Price to Sales (P/S)35.39
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.36
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Intellectual PropertyExpanded patent allowances across jurisdictions for namodenoson’s anti-obesity use deepen Can-Fite’s IP moat. Strong, broad patents support exclusivity for new indications, enabling longer-term commercial optionality and potential licensing or partnership revenue streams beyond oncology.
Late-stage Clinical ProgressHaving a Phase III oncology program plus multiple ongoing Phase II programs diversifies the pipeline and increases the probability of a near-to-medium term regulatory milestone. Positive readouts could enable conditional approvals, partnerships, or commercial launches, materially changing long-term revenue prospects.
Low Financial LeverageMinimal debt reduces default and interest-rate risk, providing financial flexibility to pursue trials or partnerships. Low leverage improves ability to raise non-debt capital or negotiate collaborations without heavy interest obligations, supporting sustainable execution of long-term R&D programs.
Bears Say
Shrinking RevenuePersistently very low and declining revenue means the company cannot self-fund development from operations. Continued top-line weakness increases dependence on external capital and raises execution risk if clinical programs need sustained funding before commercialization.
Consistent Cash BurnChronic negative operating and free cash flow indicate ongoing cash consumption to advance trials. Even with occasional improvements, sustained burn erodes runway and forces recurrent financing cycles, which can dilute shareholders and distract management from long-term strategy.
Reliance On External FinancingRepeated capital raises and modest cash balances show dependency on markets to fund operations. This structural reliance risks dilution, potential financing at unfavorable terms, and operational disruption if markets tighten while pivotal trials and milestones demand sustained funding.
Can Fite Bio News
CANF FAQ
What was Can-Fite BioPharma Ltd.’s price range in the past 12 months?
Can-Fite BioPharma Ltd. lowest stock price was 500.00 and its highest was 6000.00 in the past 12 months.
What is Can-Fite BioPharma Ltd.’s market cap?
Can-Fite BioPharma Ltd.’s market cap is ₪22.42M.
When is Can-Fite BioPharma Ltd.’s upcoming earnings report date?
Can-Fite BioPharma Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 151 days.
How were Can-Fite BioPharma Ltd.’s earnings last quarter?
Can-Fite BioPharma Ltd. released its earnings results on Mar 26, 2026. The company reported -25.728 earnings per share for the quarter, missing the consensus estimate of -21.963 by -3.765.
Is Can-Fite BioPharma Ltd. overvalued?
According to Wall Street analysts Can-Fite BioPharma Ltd.’s price is currently Overvalued.
Does Can-Fite BioPharma Ltd. pay dividends?
Can-Fite BioPharma Ltd. does not currently pay dividends.
What is Can-Fite BioPharma Ltd.’s EPS estimate?
Can-Fite BioPharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Can-Fite BioPharma Ltd. have?
Can-Fite BioPharma Ltd. has 4,285,093 shares outstanding.
What happened to Can-Fite BioPharma Ltd.’s price movement after its last earnings report?
Can-Fite BioPharma Ltd. reported an EPS of -25.728 in its last earnings report, missing expectations of -21.963. Following the earnings report the stock price went down -0.719%.
Which hedge fund is a major shareholder of Can-Fite BioPharma Ltd.?
Currently, no hedge funds are holding shares in IL:CANF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.